Watch For Continued Gains In Shares Of Eli Lilly And Company

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Eli Lilly and Company LLY traded at a new 12-month high today of $291.35. So far today approximately 749,000 shares have been exchanged, as compared to an average 30-day volume of 2.9 million shares.

Eli Lilly and Company is currently priced 1.7% above its average consensus analyst price target of $285.66.

Eli Lilly and Company share prices have moved between a 12-month high of $291.35 and a 12-month low of $178.58 and are now trading 63% above that low price at $290.58 per share.

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly’s key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.